Zydus Cadila completes Phase II of clinical trials on Covid-19 patients

Pharmaceutical company Zydus Cadila said on Thursday that it has successfully completed the second phase of clinical trials on Covid-19 patients with biological therapy ‘Pegihep’ and now the company will start the third phase of the clinical trial. Zydus Cadila told the stock market, “They have successfully completed the second phase of clinical trials on Covid-19 patients with their biological therapy … Based on the results of its second phase study, Zydus Cadila is now planning to begin phase three clinical trials in India.”  Zydus Cadila, under the Cadila Healthcare Group, said that pegylated interferon alpha-2b significantly reduced viral and overcome oxygen deficiency in patients with Covid-19.